American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 oct. 2023 08h00 HE
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
21 sept. 2023 08h30 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 sept. 2023 05h30 HE
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
06 sept. 2023 08h00 HE
|
Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
28 août 2023 06h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
01 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Sleep Apnea Devices Market Size to Reach $8.30 Billion at 7.9% CAGR with Home Healthcare Segment Driving Growth by 2025 | Report by The Insight Partners
26 juil. 2023 05h52 HE
|
The Insight Partners
Pune, India, July 26, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on “Sleep Apnea Devices Market Size Report & Share Forecast to 2025 – COVID-19 Impact and Global...
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
21 juil. 2023 09h09 HE
|
Incannex Healthcare
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
18 juil. 2023 07h40 HE
|
Incannex Healthcare
Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.The Phase 2/3...